Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 05.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | press release reflecting the matters discussed in Item 5.02 of this Current Report on Form 8-K. The full text of this pr |
Stammdaten
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Unternehmen & Branche
| Name | PMV Pharmaceuticals, Inc. |
|---|---|
| Ticker | PMVP |
| CIK | 0001699382 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 76,3 Mio. USD |
| Beta | 1,40 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -77,742,000 | -1.48 | 116,562,000 | 104,712,000 | |
| 2025-09-30 | 10-Q | -21,059,000 | -0.40 | 133,844,000 | 120,999,000 | |
| 2025-06-30 | 10-Q | -21,210,000 | -0.41 | 152,855,000 | 140,605,000 | |
| 2025-03-31 | 10-Q | -17,436,000 | -0.34 | 170,608,000 | 160,107,000 | |
| 2024-12-31 | 10-K | -58,709,000 | -1.14 | 191,288,000 | 176,080,000 | |
| 2024-09-30 | 10-Q | -19,226,000 | -0.37 | 223,495,000 | 197,908,000 | |
| 2024-06-30 | 10-Q | -1,213,000 | -0.02 | 237,539,000 | 214,316,000 | |
| 2024-03-31 | 10-Q | -15,270,000 | -0.30 | 236,876,000 | 212,676,000 | |
| 2023-12-31 | 10-K | -68,960,000 | -1.44 | 252,152,000 | 225,689,000 | |
| 2023-09-30 | 10-Q | -16,640,000 | -0.34 | 261,027,000 | 237,612,000 | |
| 2023-06-30 | 10-Q | -17,436,000 | -0.38 | 242,216,000 | 217,809,000 | |
| 2023-03-31 | 10-Q | -19,128,000 | -0.42 | 253,960,000 | 230,173,000 | |
| 2022-12-31 | 10-K | -73,317,000 | -1.61 | 270,308,000 | 246,028,000 | |
| 2022-09-30 | 10-Q | -18,229,000 | -0.40 | 284,984,000 | 261,193,000 | |
| 2022-06-30 | 10-Q | -17,310,000 | -0.38 | 300,564,000 | 276,970,000 | |
| 2022-03-31 | 10-Q | -18,433,000 | -0.41 | 315,008,000 | 291,843,000 | |
| 2021-12-31 | 10-K | -57,846,000 | -1.28 | 331,568,000 | 308,559,000 | |
| 2021-09-30 | 10-Q | -15,011,000 | -0.33 | 344,178,000 | 324,948,000 | |
| 2021-06-30 | 10-Q | -12,874,000 | 355,910,000 | 337,847,000 | ||
| 2021-03-31 | 10-Q | -11,602,000 | 354,393,000 | 348,295,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-10-23 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Sale | -1,000,000 | 1.52 | -1,520,000.00 | -354,6% | |
| 2025-09-10 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Sale | -500,000 | 1.80 | -900,000.00 | -209,9% | |
| 2025-07-01 | Ticktin Robert | Officer, General Counsel & COO | Open Market Sale | -23,151 | 1.06 | -24,651.18 | -5,8% | |
| 2025-07-01 | Carulli Michael | Officer, Chief Financial Officer | Open Market Sale | -28,249 | 1.06 | -30,076.71 | -7,0% | |
| 2025-07-01 | Mack David Henry | Director, Officer, President and CEO | Open Market Sale | -58,411 | 1.06 | -62,178.51 | -14,5% | |
| 2025-07-01 | Jalota Deepika | Officer, Chief Development Officer | Open Market Sale | -33,065 | 1.06 | -35,197.69 | -8,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.